Posted by Michael Wonder on 12 Dec 2017
SIGA Technologies announces FDA submission of its new drug application for oral TPOXX (tecovirimat) to treat smallpox
11 December 2017 - Company requests priority review of TPOXX new drug application.
SIGA Technologies today announced the submission of its new drug application to the U.S. FDA for the oral formulation of TPOXX (tecovirimat). TPOXX was developed to treat smallpox, as well as other orthopoxvirus infections. No cure or treatment for smallpox exists.
The advanced development of TPOXX has been funded by the U.S. government’s Biomedical Advanced Research and Development Authority (BARDA). Pursuant to a contract with BARDA, SIGA has successfully delivered two million courses of TPOXX to the Strategic National Stockpile.
